Modern breast cancer radiotherapy techniques appear to have reduced heart disease risk.
Older radiation techniques for left-sided breast cancer inadvertently exposed the heart to significant doses, raising cardiovascular disease risk years later. This study examined whether modern external beam radiation therapy (EBRT) techniques—using more precise delivery methods—have reduced this…
Modern breast cancer radiotherapy techniques appear to have reduced heart disease risk.
Older radiation techniques for left-sided breast cancer inadvertently exposed the heart to significant doses, raising cardiovascular disease risk years later. This study examined whether modern external beam radiation therapy (EBRT) techniques—using more precise delivery methods—have reduced this risk.
Contemporary EBRT techniques appear to have significantly reduced cardiovascular disease risk compared to older approaches, representing an important improvement in long-term breast cancer survivorship outcomes.
This finding has implications for how clinicians counsel patients about long-term radiotherapy risks.
Key Findings
- Contemporary EBRT techniques appear to reduce cardiovascular disease risk vs. older methods
- Risk reduction is relevant for left-sided breast cancer specifically
- Modern techniques include deep inspiration breath hold and intensity-modulated RT
- Finding supports the safety of current radiotherapy for breast cancer
- Cardiovascular disease remains a significant cause of death in long-term BC survivors
Implications
Long-term breast cancer survivors treated with modern EBRT may have lower cardiovascular risk than historical data suggested. Patients and oncologists should still monitor cardiac health, but the risk profile of contemporary radiotherapy is improved. Continued refinement of delivery techniques is warranted.
Caveats
RSS news abstract; limited methodological detail; abstract-only. Specific techniques, follow-up duration, and magnitude of risk reduction not detailed. Observational data—confounding by patient selection is possible.
Source: MedPage Hematology/Oncology — 2026-04-07